{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:15:18Z","timestamp":1771863318515,"version":"3.50.1"},"reference-count":179,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijrobp.2025.09.013","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:19:04Z","timestamp":1758086344000},"page":"395-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-1852","authenticated-orcid":false,"given":"Julie","family":"Dardare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Martz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Witz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Betz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Gilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Harle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.09.013_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919875568","article-title":"An update on treatment options for pancreatic adenocarcinoma","volume":"11","author":"Lambert","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0006","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0008","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser","year":"1985","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0009","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2024.42.16_suppl.4005","article-title":"NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)","volume":"42","author":"Abrams","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0010","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): A four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0012","doi-asserted-by":"crossref","first-page":"S1323","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83 neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial","volume":"34","author":"Groot Koerkamp","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0013","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0014","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0015","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0016","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbcan.2017.02.003","article-title":"Biological determinants of radioresistance and their remediation in pancreatic cancer","volume":"1868","author":"Seshacharyulu","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0019","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41575-019-0247-2","article-title":"Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers","volume":"17","author":"Buckley","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0020","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1200\/JCO.2007.11.5287","article-title":"Antimetabolite radiosensitizers","volume":"25","author":"Shewach","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0021","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1535-7163.MCT-07-0068","article-title":"Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: A new paradigm for antimetabolite radiosensitizers","volume":"6","author":"Flanagan","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0022","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/mol.107.043349","article-title":"MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches","volume":"74","author":"Flanagan","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0023","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1667\/RR14443.1","article-title":"Late DNA damage mediated by homologous recombination repair results in radiosensitization with gemcitabine","volume":"186","author":"Im","year":"2016","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0024","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","article-title":"Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma","volume":"30","author":"Schmidt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0025","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0026","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0027","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0028","first-page":"16","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0029","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","article-title":"ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications","volume":"18","author":"Armstrong","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0030","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0031","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10637-022-01216-8","article-title":"Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors","volume":"40","author":"Waqar","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0032","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0033","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1158\/1078-0432.CCR-23-0290","article-title":"ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis","volume":"29","author":"Tew","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0034","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1535-7163.MCT-23-0890","article-title":"A novel dual ATM\/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors","volume":"23","author":"Gilmer","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0036","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1172\/JCI127483","article-title":"Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy","volume":"130","author":"Willoughby","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0037","article-title":"Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0038","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0039","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-21-0725","article-title":"DNA-PK inhibition and radiation promote antitumoral immunity through RNA polymerase III in pancreatic cancer","volume":"20","author":"Wang","year":"2022","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41416-020-01151-6","article-title":"A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours","volume":"124","author":"van Bussel","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0041","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","article-title":"A phase Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer","volume":"30","author":"Romesser","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0042","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","article-title":"A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors","volume":"118","author":"Samuels","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102217","article-title":"Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors","volume":"9","author":"Perez","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0044","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/acs.jmedchem.9b01684","article-title":"The discovery of 7-methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor","volume":"63","author":"Goldberg","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2021.11.027","article-title":"Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648","volume":"166","author":"Hong","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0046","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0047","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","article-title":"Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control","volume":"27","author":"Nakamura","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0048","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1158\/0008-5472.CAN-09-3573","article-title":"Mechanism of radiosensitization by the Chk1\/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair","volume":"70","author":"Morgan","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0049","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0050","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.4161\/cc.10.24.18661","article-title":"Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1","volume":"10","author":"Vance","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0051","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","article-title":"Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia","volume":"61","author":"Webster","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0052","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0053","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0054","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","article-title":"Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy","volume":"27","author":"Fu","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0056","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.neo.2015.09.006","article-title":"Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair","volume":"17","author":"Kausar","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0057","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0058","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","article-title":"Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer","volume":"20","author":"Karnak","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0059","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tranon.2014.04.003","article-title":"Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly (ADP-ribose) polymerase inhibition with ABT-888","volume":"7","author":"Tuli","year":"2014","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0061","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0062","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167272","article-title":"Effects of combined treatment with ionizing radiation and the PARP inhibitor olaparib in BRCA mutant and wild type patient-derived pancreatic cancer xenografts","volume":"11","author":"Lohse","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0063","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination-proficient pancreatic cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0064","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.3390\/ijms22136825","article-title":"Gemcitabine-based chemoradiotherapy enhanced by a PARP inhibitor in pancreatic cancer cell lines","volume":"22","author":"Waissi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3390\/cancers13030527","article-title":"Radiosensitizing pancreatic cancer with PARP inhibitor and gemcitabine: An in vivo and a whole-transcriptome analysis after proton or photon irradiation","volume":"13","author":"Waissi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0066","doi-asserted-by":"crossref","first-page":"A070","DOI":"10.1158\/1535-7163.TARG-23-A070","article-title":"Abstract A070: Olaparib enhances radiation-induced type I interferon and sensitizes pancreatic cancer to PD-L1 immune checkpoint inhibition","volume":"22","author":"Valvo","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0067","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/JCO.2022.40.4_suppl.564","article-title":"A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer","volume":"40","author":"Parikh","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0068","doi-asserted-by":"crossref","first-page":"02TR01","DOI":"10.1088\/1361-6560\/aa99ce","article-title":"Nanoparticle radio-enhancement: Principles, progress and application to cancer treatment","volume":"63","author":"Kuncic","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0069","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijrobp.2015.09.032","article-title":"Roadmap to clinical use of gold nanoparticles for radiation sensitization","volume":"94","author":"Schuemann","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.addr.2015.12.012","article-title":"Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements","volume":"109","author":"Her","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0071","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/pharmaceutics16060806","article-title":"Prospect of gold nanoparticles in pancreatic cancer","volume":"16","author":"Yin","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0072","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512523","article-title":"Utilizing gold nanoparticles as prospective radiosensitizers in 3D radioresistant pancreatic co-culture model","volume":"24","author":"Alhussan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0073","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/pharmaceutics16070900","article-title":"Enhanced cytotoxicity against a pancreatic cancer cell line combining radiation and gold nanoparticles","volume":"16","author":"Martins","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0074","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/acsabm.8b00766","article-title":"Gold nanoparticle-incorporated molecularly imprinted microgels as radiation sensitizers in pancreatic cancer","volume":"2","author":"Yoshida","year":"2019","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/pharmaceutics16060713","article-title":"In vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer","volume":"16","author":"Alhussan","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0076","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.3390\/cancers14123034","article-title":"Biodegradable ultrasmall-in-nano architectures loaded with cisplatin prodrug in combination with ionizing radiation induces DNA damage and apoptosis in pancreatic ductal adenocarcinoma","volume":"14","author":"Che","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0077","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1166\/jnn.2011.4725","article-title":"In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells","volume":"11","author":"Mowat","year":"2011","journal-title":"J Nanosci Nanotechnol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0078","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12645-014-0006-6","article-title":"Cell localisation of gadolinium-based nanoparticles and related radiosensitising efficacy in glioblastoma cells","volume":"5","author":"\u0160tefan\u010d\u00edkov\u00e1","year":"2014","journal-title":"Cancer Nanotechnol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0079","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.nano.2014.06.004","article-title":"Radiation dose enhancement of gadolinium-based AGuIX nanoparticles on HeLa cells","volume":"10","author":"Luchette","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12645-015-0012-3","article-title":"AGuIX nanoparticles as a promising platform for image-guided radiation therapy","volume":"6","author":"Detappe","year":"2015","journal-title":"Cancer Nanotechnol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0081","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2016.07.021","article-title":"Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy","volume":"238","author":"Detappe","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0082","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2147\/IJN.S301182","article-title":"NBTXR3 radiotherapy-activated functionalized hafnium oxide nanoparticles show efficient antitumor effects across a large panel of human cancer models","volume":"16","author":"Zhang","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0083","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1748-717X-9-150","article-title":"Hafnium oxide nanoparticles: Toward an in vitro predictive biological effect?","volume":"9","author":"Marill","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0084","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","article-title":"First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas","volume":"23","author":"Bonvalot","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0085","first-page":"66","article-title":"NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience","volume":"33","author":"Bagley","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0086","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/1078-0432.CCR-06-2534","article-title":"130-nm albumin\u2013bound paclitaxel enhances tumor radiocurability and therapeutic gain","volume":"13","author":"Wiedenmann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0087","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1040-8428(01)00184-6","article-title":"Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer","volume":"43","author":"Safran","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0088","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-018-3519-6","article-title":"A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer","volume":"81","author":"Shabason","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0089","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/COC.0000000000000854","article-title":"Concurrent nab-paclitaxel and radiotherapy: Novel radiosensitization for borderline resectable or unresectable pancreatic cancer","volume":"44","author":"Arscott","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0090","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1158\/1078-0432.CCR-15-1883","article-title":"Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease","volume":"22","author":"Hutcheson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0091","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0092","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","article-title":"Radiotherapy and immunotherapy: Open questions and future strategies","volume":"8","author":"Pointer","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100867","article-title":"Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization","volume":"36","author":"Rajeev-Kumar","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0094","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0095","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","article-title":"Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming","volume":"76","author":"Rodriguez-Ruiz","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0096","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15252\/emmm.201606674","article-title":"PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","volume":"9","author":"Azad","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0097","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0098","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0099","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0100","article-title":"PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: A biomolecular exploratory, phase II trial","volume":"4","author":"Du","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0101","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: An open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Zhu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109941","article-title":"Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial","volume":"190","author":"Zhu","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0103","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0105","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0107","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0108","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216859","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities","volume":"591","author":"Qin","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13046-024-03251-0","article-title":"Cancer-associated fibroblasts, tumor and radiotherapy: Interactions in the tumor micro-environment","volume":"43","author":"Raaijmakers","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0111","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41419-023-06060-z","article-title":"Cancer-associated fibroblasts: Tumor defenders in radiation therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211117","article-title":"Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma","volume":"14","author":"Gunderson","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0113","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0114","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0115","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0116","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tranon.2016.07.004","article-title":"Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma","volume":"9","author":"Kumar","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2020.07.015","article-title":"Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation","volume":"493","author":"Wadsworth","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0118","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0119","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.719","article-title":"A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)","volume":"41","author":"Hong","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0121","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1038\/s41467-020-18636-w","article-title":"Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer","volume":"11","author":"Kocher","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0122","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2021.02.012","article-title":"Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts","volume":"172","author":"Liu","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0123","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0124","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/ijms21103534","article-title":"SMAD4 and the TGF\u03b2 pathway in patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Dardare","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104745","article-title":"TGF-\u03b2 in radiotherapy: Mechanisms of tumor resistance and normal tissues injury","volume":"155","author":"Farhood","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0126","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1541-7786.MCR-21-0612","article-title":"DNA-PK inhibitor peposertib amplifies radiation-induced inflammatory micronucleation and enhances TGF\u03b2\/PD-L1 targeted cancer immunotherapy","volume":"20","author":"Carr","year":"2022","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0127","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0129","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0131","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006432","article-title":"Pre-existing TGF-\u03b2-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy","volume":"11","author":"Mortensen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0132","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications","volume":"9","author":"Erkan","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0134","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semcancer.2023.11.006","article-title":"Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities","volume":"98","author":"Beckers","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0136","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pan.2014.06.008","article-title":"Hypoxia-inducible factor 1\u03b1 expression and its clinical significance in pancreatic cancer: A meta-analysis","volume":"14","author":"Ye","year":"2014","journal-title":"Pancreatology"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0137","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/OTT.S158206","article-title":"The role of HIF-1\u03b1 in chemo-\/radioresistant tumors","volume":"11","author":"Xia","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0138","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1535-7163.MCT-09-0768","article-title":"Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer","volume":"9","author":"Schwartz","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0139","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ijc.32227","article-title":"Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer","volume":"145","author":"Nagaraju","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1158\/2159-8290.CD-15-0822","article-title":"Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia","volume":"6","author":"Lee","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0141","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","article-title":"Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy","volume":"98","author":"Mistry","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0142","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122634","article-title":"Nano-sensitizer with self-amplified drug release and hypoxia normalization properties potentiates efficient chemoradiotherapy of pancreatic cancer","volume":"310","author":"Yu","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0143","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.pan.2024.11.003","article-title":"The combined effect of hypoxia activation and radiosensitization by a multifunctional nanoplatform system enhances the therapeutic efficacy of chemoradiotherapy in pancreatic cancer","volume":"24","author":"Pan","year":"2024","journal-title":"Pancreatology"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0144","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: The tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0145","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0146","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00066-020-01666-0","article-title":"FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro","volume":"197","author":"Mohamed","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0147","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0148","doi-asserted-by":"crossref","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2020.0273","article-title":"Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells","volume":"18","author":"Osipov","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113114","article-title":"Low-dose X-ray irradiation combined with FAK inhibitors improves the immune microenvironment and confers sensitivity to radiotherapy in pancreatic cancer","volume":"151","author":"Chen","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0150","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0151","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1108776","article-title":"The role of metabolic reprogramming in pancreatic cancer chemoresistance","volume":"13","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0152","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/1078-0432.CCR-19-1543","article-title":"Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer","volume":"26","author":"Karasinska","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0153","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/1078-0432.CCR-19-2926","article-title":"Metabolic subtyping for novel personalized therapies against pancreatic cancer","volume":"26","author":"Mehla","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0154","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2017.03.026","article-title":"Drug resistance in pancreatic cancer: Impact of altered energy metabolism","volume":"114","author":"Grasso","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0155","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1158\/1078-0432.CCR-17-1151","article-title":"MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer","volume":"23","author":"Gunda","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0156","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0157","doi-asserted-by":"crossref","first-page":"13787","DOI":"10.1073\/pnas.1203339109","article-title":"MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer","volume":"109","author":"Chaika","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0158","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110606","article-title":"A metabolic switch to the pentose-phosphate pathway induces radiation resistance in pancreatic cancer","volume":"202","author":"Shimoni-Sebag","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0159","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1470-2045(17)30314-5","article-title":"Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial","volume":"18","author":"Alistar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0160","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.23.02659","article-title":"Devimistat (CPI-613) with modified fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: The phase III AVENGER 500 study","volume":"42","author":"Philip","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0161","article-title":"Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiation therapy","volume":"8","author":"Khan","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0162","doi-asserted-by":"crossref","first-page":"CT080","DOI":"10.1158\/1538-7445.AM2024-CT080","article-title":"Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma","volume":"84","author":"Kamgar","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0163","first-page":"1141","article-title":"Role of superoxide dismutase in cancer: A review","volume":"39","author":"Oberley","year":"1979","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0164","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1515\/hsz-2014-0234","article-title":"Extracellular localization of catalase is associated with the transformed state of malignant cells","volume":"396","author":"B\u00f6hm","year":"2015","journal-title":"Biol Chem"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10715761003667554","article-title":"Reactive oxygen species in cancer","volume":"44","author":"Liou","year":"2010","journal-title":"Free Radic Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0166","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20081258","article-title":"Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation","volume":"418","author":"Aykin-Burns","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0167","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2016.10.010","article-title":"Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy","volume":"10","author":"Doskey","year":"2016","journal-title":"Redox Biol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0168","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.freeradbiomed.2020.07.032","article-title":"The novel SOD mimetic GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells","volume":"160","author":"El-Mahdy","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0169","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2008.10.030","article-title":"A recombinant MnSOD is radioprotective for normal cells and radiosensitizing for tumor cells","volume":"46","author":"Borrelli","year":"2009","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijrobp.2017.10.019","article-title":"Phase 1b\/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma","volume":"100","author":"Anderson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0171","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.19.01507","article-title":"Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer","volume":"37","author":"Anderson","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0172","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1200\/JCO.2022.40.16_suppl.6005","article-title":"ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC)","volume":"40","author":"Anderson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0173","doi-asserted-by":"crossref","first-page":"eabb3768","DOI":"10.1126\/scitranslmed.abb3768","article-title":"Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide","volume":"13","author":"Sishc","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0174","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S1470-2045(23)00478-3","article-title":"Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: An adaptive, randomised, double-blind, placebo-controlled, phase 1b\/2 trial","volume":"24","author":"Taniguchi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2217\/fon-2022-1219","article-title":"Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design","volume":"20","author":"Hoffe","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0176","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1667\/RR14668.1","article-title":"Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: The University of Iowa experience of two phase I clinical trials","volume":"187","author":"Zahra","year":"2017","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0177","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41416-022-01965-6","article-title":"Sensitisation of cancer cells to radiotherapy by serine and glycine starvation","volume":"127","author":"Falcone","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0178","doi-asserted-by":"crossref","DOI":"10.1038\/sj.embor.7400422","article-title":"Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans","author":"Demetrius","year":"2005","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ijrobp.2025.09.013_bib0179","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/advances\/nmaa062","article-title":"Perspective: Do fasting, caloric restriction, and diets increase sensitivity to radiotherapy? A literature review","volume":"11","author":"Icard","year":"2020","journal-title":"Adv Nutr"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:45:16Z","timestamp":1771861516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625062753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":179,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0360301625062753"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.013","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}